<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823342</url>
  </required_header>
  <id_info>
    <org_study_id>2008-000733-21</org_study_id>
    <secondary_id>ANRS HB 05</secondary_id>
    <nct_id>NCT00823342</nct_id>
  </id_info>
  <brief_title>ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy</brief_title>
  <official_title>ANRS HB 05 : A Randomized, Double Blind, Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmasset</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For chronic HBV infection, an optimal pharmacological agent to promote recovery from chronic&#xD;
      HBV infection would be one that inhibits HBV DNA polymerase, combined with the clearence from&#xD;
      the liver of cccDNA to block HBV reactivation after the circulating viral burden has been&#xD;
      eliminated by therapy. The activity of clevudine on cccDNA in combination with its potent&#xD;
      antiviral activity on HBV polymerase makes it the optimal agent in combination with tenofovir&#xD;
      for this protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the long term efficacy of new anti-HBV strategies of CLV monotherapy VS TDF monotherapy VS the combination of CLV + TDF for 96 weeks in HBeAg negative patients with CHB, naïve to anti-HBV-therapy, at 24 weeks post-treatment</measure>
    <time_frame>At 120 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the safety profile of CLV + TDF compared to that of CLV and TDF in HBeAg negative patients with CHB, naïve to anti-HBV-therapy. - To compare perceived toxicity as expressed by the nature and the number of self-reported side effects, percept</measure>
    <time_frame>At 24 week, 48 week and 96 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HBe Negative Chronic Hepatitis B</condition>
  <condition>Hepatitis B Viral Infection</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CLEVUDINE 30 mg qd + TENOFOVIR Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TENOFOVIR 300 mg qd + CLEVUDINE Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLEVUDINE + TENOFOVIR PLACEBO</intervention_name>
    <description>30 MG</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLEVUDINE IN ASSOCIATION TENOFOVIR</intervention_name>
    <description>TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TENOFOVIR + CLEVUDINE PLACEBO</intervention_name>
    <description>TENOFOVIR 300 mg qd + CLEVUDINE Placebo</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients over 18 years of age&#xD;
&#xD;
          -  Chronic hepatitis B, HBs Ag-positive for over 6 months, anti HBs negative&#xD;
&#xD;
          -  Patients with HBeAg- negative chronic hepatitis B (CHB) and anti-HBe positive at&#xD;
             screen&#xD;
&#xD;
          -  Patients naïve to anti-HBV nucleoside or nucleotide and any other experimental&#xD;
             nucleoside/nucleotide analog for HBV&#xD;
&#xD;
          -  Serum HBV-DNA quantifiable over 2000 IU/mL at screening&#xD;
&#xD;
          -  ALT over 1.25 ULN and below 10 ULN&#xD;
&#xD;
          -  Liver biopsy (baseline or within prior 6 months) with evidence of chronic hepatic&#xD;
             inflammatory injury (Metavir Activity score over 1 ; Knodell necroinflammatory score&#xD;
             over 3, Ishak score over 1)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis or bridging fibrosis on liver biopsy&#xD;
&#xD;
          -  Subjects who have received any form of alpha interferon in the past 6 months prior to&#xD;
             the first administration of randomized treatment&#xD;
&#xD;
          -  Any systemic anti-viral, anti-neoplastic or immuno-modulatory treatment (including&#xD;
             supraphysiologic doses of steroids and radiation) below 6 months prior to the first&#xD;
             dose of randomized treatment and during the study (except for below 10 days of&#xD;
             acyclovir for herpetic lesions, or prednisone below 10 mg/days for below 10 days more&#xD;
             than 1 month)&#xD;
&#xD;
          -  Women with ongoing pregnancy or breast feeding&#xD;
&#xD;
          -  Positive test at screening for anti-HAV IgM Ab, anti-HIV Ab, anti-HCV Ab, HCV RNA,&#xD;
             anti-HDV Ab&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HBV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease&#xD;
             including Wilson's disease and alpha1-antitrypsin deficiency, alcoholic liver disease,&#xD;
             toxin exposures, toxic thalassemia, NASH)&#xD;
&#xD;
          -  History or other evidence of bleeding from esophageal varices or other clinical&#xD;
             conditions consistent with decompensated liver disease (defined by one of the&#xD;
             following criteria being met: serum albumin below 3.5 g/L, prothrombin time over 4&#xD;
             seconds prolonged, serum bilirubin over 34 µmol/L, history of encephalopathy, history&#xD;
             of ascites)&#xD;
&#xD;
          -  Neutrophil count below 1200 cells/mm3 or platelet count below 90,000 cells/mm3 at&#xD;
             screening&#xD;
&#xD;
          -  Serum creatinine level over 130µmol/l or calculated creatinine clearance below 70&#xD;
             ml/min (Cockcroft-Gault)&#xD;
&#xD;
          -  Evidence or history of tubular nephropathy , Fanconi syndrom or hypophosphoremia.&#xD;
&#xD;
          -  Evidence of drug abuse (including excessive alcohol consumption) within one year of&#xD;
             study entry&#xD;
&#xD;
          -  History of a severe seizure disorder or current anticonvulsant use&#xD;
&#xD;
          -  History of immunologically mediated disease (e.g., inflammatory bowel disease,&#xD;
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia,&#xD;
             scleroderma, severe psoriasis, rheumatoid arthritis etc.)&#xD;
&#xD;
          -  History of major organ transplantation with an existing functional graft&#xD;
&#xD;
          -  History or other evidence of severe illness or any other conditions which would make&#xD;
             the patient, in the opinion of the investigator, unsuitable for the study&#xD;
&#xD;
          -  Evidence of an active or suspected cancer or a history of malignancy where the risk of&#xD;
             recurrence is over 20 % within 2 years&#xD;
&#xD;
          -  Patients with a value of alpha-fetoprotein over 100 ng/mL are excluded, unless&#xD;
             stability (less than 10 % increase) has been documented over at least the previous 3&#xD;
             months&#xD;
&#xD;
          -  Patients included in another trial within 8 weeks prior to screening&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent or abide by the requirements of&#xD;
             the study Reassessments : If a patient fails to meet the above inclusion /exclusion&#xD;
             criteria for a reason thought to be reversible, that patient may be reassessed for&#xD;
             entry on two additional occasions at most. If the parameter out of range for inclusion&#xD;
             was ALT over 10 x ULN, the patient should be reassessed over 4 weeks after the date&#xD;
             corresponding to the value that was over 10 x ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARC BOURLIERE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Joseph, marseille, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <last_update_submitted>May 7, 2009</last_update_submitted>
  <last_update_submitted_qc>May 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Karim Kaabeche/regulatory affairs</name_title>
    <organization>ANRS</organization>
  </responsible_party>
  <keyword>HBe, Hepatitis, Vireda (TENOFOVIR, CLEVUDINE), HBV, HBe Ag negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

